Cara Therapeutics (CARA) Gets BidaskScore Higher Rating; Muniyield Pennsylvania Insured Fund (MPA) Sentiment Is 3

Cara Therapeutics, Inc. (NASDAQ:CARA) Logo

Muniyield Pennsylvania Insured Fund (MPA) investors sentiment increased to 3 in 2019 Q2. It’s up 2.27, from 0.73 in 2019Q1. The ratio is positive, as 8 hedge funds increased and started new positions, while 11 cut down and sold positions in Muniyield Pennsylvania Insured Fund. The hedge funds in our database reported: 1.17 million shares, down from 1.34 million shares in 2019Q1. Also, the number of hedge funds holding Muniyield Pennsylvania Insured Fund in top ten positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 9 Increased: 4 New Position: 4.

In a analysts report shared with investors and clients on Tuesday morning, investment analysts at BidaskScore’s equity division boosted Cara Therapeutics (NASDAQ:CARA)‘s stock to a Buy.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $800.31 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

The stock increased 1.24% or $0.21 during the last trading session, reaching $17.15. About 2.13 million shares traded or 229.74% up from the average. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 33.82% since December 4, 2018 and is uptrending. It has outperformed by 33.82% the S&P500. Some Historical CARA News: 23/05/2018 – CARA TO GET $70M INVESTMENT UP FRONT; UP TO $470M MILESTONES; 10/04/2018 – Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation; 09/05/2018 – Cara Therapeutics Presenting at Conference May 16; 15/03/2018 – Cara Therapeutics 4Q Loss/Shr 43c; 23/05/2018 – CARA THERAPEUTICS INC – CARA ELIGIBLE FOR UP TO $470 MLN IN REGULATORY AND COMMERCIAL MILESTONES; 12/03/2018 – Sen. Hassan: Senator Hassan Leads Roundtable Discussion on Importance of Passing Bipartisan CARA 2.0 Act to Support Public; 23/05/2018 – CARA THERAPEUTICS INC – CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES; 23/05/2018 – Cara Therapeutics Closes Above 200-Day Average: Technicals; 23/05/2018 – Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercializ; 09/03/2018 – CARA OPERATIONS LTD – QTRLY EARNINGS PER SHARE FROM CONTINUING OPERATIONS ATTRIBUTABLE TO COMMON SHAREHOLDERS $0.45

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Finance.Yahoo.com which released: “Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78% – Yahoo Finance” on December 04, 2019, also Nasdaq.com with their article: “Why Cara Therapeutics Stock Is Plunging Today – Nasdaq” published on December 03, 2019, Nasdaq.com published: “Why Peloton Interactive, Plug Power, and Cara Therapeutics Slumped Today – Nasdaq” on December 03, 2019. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Nasdaq.com and their article: “ARDX Jumps On PHREEDOM Data, AXSM Is Awesome, CARA On Watch – Nasdaq” published on December 04, 2019 as well as Nasdaq.com‘s news article titled: “Is Cara Therapeutics a Buy? – Nasdaq” with publication date: November 20, 2019.

Among 3 analysts covering Cara Therapeutics (NASDAQ:CARA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics has $3900 highest and $33 lowest target. $35.67’s average target is 107.99% above currents $17.15 stock price. Cara Therapeutics had 6 analyst reports since July 30, 2019 according to SRatingsIntel. Needham maintained Cara Therapeutics, Inc. (NASDAQ:CARA) rating on Thursday, October 17. Needham has “Buy” rating and $35 target. On Monday, October 14 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Overweight” rating given on Tuesday, July 30 by Piper Jaffray.

Investors sentiment increased to 1.81 in 2019 Q2. Its up 0.10, from 1.71 in 2019Q1. It is positive, as 11 investors sold Cara Therapeutics, Inc. shares while 24 reduced holdings. 17 funds opened positions while 43 raised stakes. 24.80 million shares or 19.04% more from 20.83 million shares in 2019Q1 were reported. 2,454 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Creative Planning has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). C World Wide Gru Holdg A S has 703,460 shares. Goldman Sachs, a New York-based fund reported 89,544 shares. New York-based Alliancebernstein L P has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Ameritas Prtn Incorporated owns 2,765 shares or 0% of their US portfolio. Alphamark Advsrs Ltd Company accumulated 1,465 shares. Winslow Evans & Crocker Inc stated it has 2,980 shares. Rho Cap Prns Inc reported 3.27 million shares. Ubs Asset Mgmt Americas reported 16,660 shares. Federated Invsts Pa reported 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Morgan Stanley reported 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Wellington Mgmt Llp has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). D E Shaw And Company reported 43,623 shares or 0% of all its holdings. Price T Rowe Assocs Inc Md reported 0.01% stake.

Analysts await Cara Therapeutics, Inc. (NASDAQ:CARA) to report earnings on March, 10. They expect $-0.63 earnings per share, down 21.15% or $0.11 from last year’s $-0.52 per share. After $-0.74 actual earnings per share reported by Cara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -14.86% EPS growth.

Since January 1, 0001, it had 0 buys, and 1 sale for $82.60 million activity.

BlackRock MuniYield Pennsylvania Quality Fund is a closed ended fixed income mutual fund launched by BlackRock, Inc. The company has market cap of $188.81 million. It is managed by BlackRock Advisors, LLC. It has a 9.91 P/E ratio. The fund invests in fixed income markets.

Mariner Investment Group Llc holds 0.57% of its portfolio in BlackRock MuniYield Pennsylvania Quality Fund for 23,160 shares. Robinson Capital Management Llc owns 91,002 shares or 0.42% of their US portfolio. Moreover, Landscape Capital Management L.L.C. has 0.08% invested in the company for 67,244 shares. The New York-based Saba Capital Management L.P. has invested 0.08% in the stock. Sit Investment Associates Inc, a Minnesota-based fund reported 164,985 shares.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.